Kyle R A, Garton J P
Mayo Clin Proc. 1987 Aug;62(8):719-31. doi: 10.1016/s0025-6196(12)65225-2.
IgM monoclonal gammopathy consists of a broad spectrum of diseases, ranging from apparently benign to malignant conditions. In a long-term follow-up study of 430 patients in whom a monoclonal IgM serum protein had been identified, 242 (56%) had monoclonal gammopathy of undetermined significance, 71 (17%) had Waldenström's macroglobulinemia, 28 (7%) had lymphoma, 21 (5%) had chronic lymphocytic leukemia, 6 (1%) had primary amyloidosis, and 62 (14%) had other malignant lymphoproliferative diseases. More than two-thirds of the patients died, and the most common cause of death was a lymphoid malignant process. Almost a fifth of the patients with an apparently benign monoclonal gammopathy subsequently had a lymphoid malignant lesion (in one patient, more than 20 years after the detection of the serum M protein). The median duration of time from the recognition of the M protein until the development of a malignant lymphoid disease ranged from 4 to 9 years. An increased number of lymphocytes or plasma cells on bone marrow examination was not a reliable indicator of the likelihood of such an outcome. Thus, follow-up of these patients should be conducted indefinitely.
IgM单克隆丙种球蛋白病包括一系列广泛的疾病,从明显良性到恶性情况不等。在一项对430例已鉴定出单克隆IgM血清蛋白患者的长期随访研究中,242例(56%)患有意义未明的单克隆丙种球蛋白病,71例(17%)患有华氏巨球蛋白血症,28例(7%)患有淋巴瘤,21例(5%)患有慢性淋巴细胞白血病,6例(1%)患有原发性淀粉样变性,62例(14%)患有其他恶性淋巴增殖性疾病。超过三分之二的患者死亡,最常见的死亡原因是淋巴样恶性病变。几乎五分之一的明显良性单克隆丙种球蛋白病患者随后出现了淋巴样恶性病变(其中1例患者在血清M蛋白检测后20多年出现)。从识别M蛋白到发生恶性淋巴样疾病的中位时间为4至9年。骨髓检查中淋巴细胞或浆细胞数量增加并不是这种结果可能性的可靠指标。因此,应对这些患者进行无限期随访。